Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous G-CSF-mobilized peripheral blood CD34+ cell transplantation for chronic kidney disease
jRCTb030240024Recruiting
- Start
- Jun 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous CD34+ cells and filgrastim in chronic kidney disease (CKD). Primary endpoints: Safety and efficacy over 24 weeks, Renal events and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
autologous CD34+ cellsfilgrastim
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTb030240024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb030240024.